The CRASH trial protocol (Corticosteroid randomisation after significant head injury) [ISRCTN74459797]. by The CRASH trial management group & The CRASH trial collaborators
(2001) The CRASH trial protocol (Corticosteroid randomisation after
significant head injury). BMC Emerg Med, 1. p. 1. ISSN 1471-227X
Downloaded from: http://researchonline.lshtm.ac.uk/20208/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
BMC Emergency Medicine (2001) 1:1 http://www.biomedcentral.com/1471-227X/1/1
BMC Emergency Medicine (2001) 1:1Research article
The CRASH trial protocol (Corticosteroid randomisation after 
significant head injury) [74459797]
The CRASH trial management group, on behalf of the CRASH trial 
collaborators 
Address: CRASH Co-ordinating Centre, FREEPOST LON 14211, London, WC1B 3BR, UK.
E-mail: crash@lshtm.ac.uk
Abstract
Background:  Worldwide, millions of people are treated each year for significant head injury. A
substantial proportion die, and many more are disabled. If short term corticosteroid infusion could
be reliably shown to reduce these risks by just a few percent then this might affect the treatment
of a few hundred thousand patients a year, protecting thousands from death or long term disability.
Study design:  CRASH is a large simple, placebo-controlled trial of the effects of a 48-hour
infusion of corticosteroids on death and on neurological disability, among adults with head injury
and some impairment of consciousness. Head injured patients with impaired consciousness who
are judged to be 16 years or older are eligible if the responsible doctor is, for any reason,
substantially uncertain whether or not to use corticosteroids.
Organisation:  The CRASH trial will determine reliably the effects on death and disability of a
short corticosteroid infusion following significant head injury. To detect or refute improvements
of only a few percent in outcome, many thousands of acute head injury patients must be
randomised between control and steroid infusions. Such large numbers will be possible only if
hundreds of doctors and nurses can collaborate in the participating emergency departments. Since
they are busy, and working in emergency situations, the trial involves them in almost no extra work:
no special investigations or changes to usual management are required, and data collection is
absolutely minimal. The trial is on-going and new collaborators are welcome. Further information
about the trial is available at www.crash.lshtm.ac.uk
Background
Corticosteroids in head injury
Worldwide, some millions of people are treated each
year for serious head injury, of whom close to a million
die, and a similar number are disabled [1], often with
profound effects on the subsequent quality of life of the
affected individuals and their carers [2]. If a treatment as
simple as short term corticosteroids produces just a
moderate benefit, this could be worthwhile. For exam-
ple, if corticosteroids reduced the risk of death by just 2%
(e.g. from 15% to 13%), and reduced the risk of perma-
nent disability by a similar amount, then treatment of
500,000 patients would avoid 10,000 deaths and pre-
vent 10,000 permanent disabilities. But, such a benefit
would be impossible to demonstrate reliably without
large scale randomised evidence. If, for example, 10,000
patients were randomly allocated to receive a corticos-
teroid infusion and 10,000 a placebo infusion, then a re-
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duction from 15% to 13% dead should be detectable - and
a reduction from 15% to 12% would certainly be detecta-
ble. By contrast, a trial involving only 2,000 patients
would probably miss such differences.
So far, all of the randomised trials of corticosteroids in
head injury have been small: the largest included only a
few hundred patients, and even in aggregate they have
involved only about 2,000 patients (Table 1) [3]. When
all previous trials are combined, the risk of death in the
corticosteroid treated group appears to be about 2% low-
er than in the control group, but the 95% confidence in-
terval runs from 6% lower to 2% higher mortality. (This
overall reduction from 39% dead to 37% dead corre-
sponds to an 'odds ratio' of 0.91, with 95% confidence in-
terval 0.74 to 1.12; the corresponding odds ratio for
death or disability in those trials is 0.90, with 95% confi-
dence interval 0.72 to 1.11.) Hence, the overall result
from the previous trials is compatible with there being no
real benefit, but it is also easily compatible with a benefit
of a few percent. However, the existing trials are too
small to demonstrate or to refute either possibility.
Corticosteroids in spinal injury
Recent evidence of benefit from corticosteroids in acute
spinal cord injury has renewed interest in their possible
role in brain injury. The Second US National Acute Spi-
nal Cord Injury Study (NASCIS 2) compared 24 hours of
methylprednisolone (MP) vs placebo in 333 patients
with acute spinal cord injury [4]. At six months, patients
who had received steroids rather than placebo appeared
to have greater improvement in motor function, and in
sensation to pinprick and touch. Similar results were re-
ported in a Japanese trial of the same regimen [5]. Re-
cent trials of MP in acute spinal cord injury have
indicated slightly more neurological recovery with 48
than with 24 hours of treatment [6].
Dose selection
Post-traumatic neuronal degeneration can involve lipid
peroxidation [7], and in cats [8,9] and mice [10] this can
be inhibited by methylprednisolone [11], with 30 mg/kg
needed for maximal effect. The dose of steroid used in
previous head injury trials was, however, much lower
than this [3], and so a trial of the early administration of
methylprednisolone in doses that are high enough to in-
hibit lipid peroxidation may produce slightly greater
treatment effects than those in Table 1. The CRASH trial
has therefore been designed to determine reliably:
• the effects of high dose corticosteroid infusion on death
and on disability following significant head injury, and
• the effects of such infusion on the risk of infection and
of gastro-intestinal bleeding in this setting.
Study design
Summary
CRASH is a large simple, placebo-controlled trial of the
effects of a 48-hour infusion of corticosteroids on death
and on neurological disability, among adults with head
injury and some impairment of consciousness. Head in-
jured patients with impaired consciousness who are
judged to be 16 years or older are eligible if the responsi-
ble doctor is, for any reason, substantially uncertain
whether or not to use corticosteroids. Numbered drug or
placebo packs will be available in each participating
Emergency Department. Randomisation involves calling
a 24 hour free phone service. The call should last only a
minute or two, and at the end of it the service will specify
to the caller which numbered treatment pack to use. The
drug or placebo in the pack is made up in saline and, fol-
lowing a one-hour loading dose, is infused over 48 hours
(or as close to 48 hours as possible). No extra tests are re-
quired, but a short form must be completed 2 weeks later
(or after prior death or discharge).
Number of patients needed
Two main factors determine the number of patients
needed in a trial. These are the estimated event rate, and
the size of the treatment effect.
Estimated event rate: In a recent multi-centre ran-
domised trial in head injury using inclusion criteria sim-
ilar to those in the CRASH trial, the overall risk of death
among controls was 15%, with the risk of unfavourable
outcome (dead, unfit for work or needing rehabilitation)
being 43% [12]. This trial is one of the most recent ran-
domised trials of corticosteroids in head injury and it
would be reasonable to expect a similar risk of unfavour-
able outcome in the CRASH trial.
Table 1: Aggregate mortality results from 13 randomised trials of 
steroids in head injury published before 1997
Steroid Control
No. of patients 1,061 1,087
No. who died 396 422
(37%) (39%)
Absolute benefit of steroids 2%, indicating 1 death prevented 
for every 50 patients treated: but these previous trial results 
are also statistically compatible with there being no real ben-
efit at all (or even a small hazard).
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Size of treatment effect that should be detectable: Be-
cause even a 2% survival advantage for an intervention
as simple and widely practicable as corticosteroids would
represent a worthwhile benefit, the current trial has been
planned to be able to detect a benefit of this size.
Numbers needed: If the real mortality difference is 15%
vs 13% then there is about a 65% chance that a trial in-
volving 10,000 patients will achieve 2P <0.01, and a 95%
chance that a trial involving 20,000 patients will do so.
These calculations assess how well the trial is protected
against an unfavourable play of chance. If however, as
might well be the case, the actual results are not much
distorted by the play of chance and involve 15% vs 13%
mortality then a trial of 10,000 would yield 2P = 0.004,
and a trial of 20,000 would yield 2P = 0.00004 (which is
extreme enough to allow some exploratory sub-analyses
of which types of patient seem most likely to benefit).
Eligibility
• Head injured patients (judged to be 16 years or older)
within 8 hours of injury who are not fully conscious (any
abnormality on the Glasgow Coma Scale), except those
for whom corticosteroids are thought to be clearly indi-
cated or contra-indicated.
Figure 1
Potentially Eligible 
Head injured patients (judged to be 16 years or 
older) within 8 hours of injury who are not fully 
conscious (any abnormality on the Glasgow Coma 
Scale) 
 
TELEPHONE FOR RANDOMISATION 
Doctor is 
substantially uncertain  
as to the appropriateness of steroids in this patient 
Doctor is reasonably certain  
that steroids are contra-indicated. 
Ineligible - don t give steroids 
and don t randomise 
 
Doctor is reasonably certain  
that steroids are indicated. 
Ineligible - give steroids and 
don t randomise 
 
STEROID PLACEBO
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All head injured patients who - in the absence of sedation
- are observed whilst in hospital to have GCS of 14 or less,
and are within 8 hours of the injury, are eligible for trial
entry if they appear to be at least 16 years old. Although
entry is allowed up to 8 hours from injury, the earlier that
patients can be treated the better.
There are no other pre-specified exclusion criteria, as the
fundamental eligibility criterion is the responsible doc-
tor's "uncertainty" whether or not to use corticosteroids
in a particular adult with head injury (Figure 1) [13]. Pa-
tients for whom there is considered by the responsible
doctor to be a clear indication for corticosteroids (such
as, perhaps, those who also have an acute spinal cord in-
jury) should not be randomised. Likewise, any for whom
there is considered to be a clear contraindication to cor-
ticosteroids should not be randomised. But, all those for
whom the responsible doctor is substantially uncertain
as to whether or not to give corticosteroids are eligible for
randomisation, and as many such patients as possible
should be considered for the trial.
Heterogeneity of the types of patients entering such a tri-
al is a scientific strength, not a weakness. If a wide range
of patients are randomised then it may be possible for a
really big trial such as this one to help determine which
(if any) particular types of patient are most likely to ben-
efit from treatment. Special eligibility considerations:
None. Routine exclusion of patients with gastrointestinal
complaints or pregnancy is unnecessary, unless the re-
sponsible doctor considers these to be a definite con-
traindication. This short term corticosteroid regimen
should not cause serious gastrointestinal bleeding, nor
should it cause a large increase in infection. Although
prolonged use of corticosteroids in pregnancy may affect
fetal adrenocortical development, this short term treat-
ment should not do so.
Consent
Patients with head injury and impaired consciousness
may be unable to give properly informed consent, and in
this emergency situation it may not be medically appro-
priate to delay the start of treatment until proxy consent
can be obtained. Hence, the doctor in charge should take
responsibility for entering such patients, just as they
would take responsibility for choosing other treatments.
However, the requirements of the relevant ethics com-
mittee should be adhered to at all times. An information
leaflet on the study for patients and their friends and rel-
atives will be available in all drug packs.
Randomisation
Patients eligible for inclusion should be randomised, and
the study treatment started, as soon as possible. Ran-
domisation is done by telephoning a 24-hour toll-free
service and takes only about two minutes. The patient
entry form (Figure 2) shows the questions that will be
asked by the telephone operator prior to allocation of the
treatment packs. The study computer will then randomly
assign a treatment pack number that will identify one of
the CRASH treatment packs stored in the emergency de-
partment. Once a patient has been randomised, we will
definitely wish to learn the outcome in hospital, even if
the trial treatment gets interrupted or is not actually giv-
en.
Study treatment [Table 2]
Each CRASH treatment pack contains:
• 11 × 2 g vials of methylprednisolone (MP) or placebo
• 1 × 20 mL sterile water for injection (for use with the
loading dose)
• 1 × 100 mL bag of 0.9% NaCl (for use with the loading
dose)
• CRASH stickers (for attaching to infusion bags and pa-
tient notes)
• Patient information leaflet and early outcome forms
Loading
2 g MP (or matching placebo) over 1 hour in 100 mL in-
fusion:
1. Add 20 mL water for injection to one 2 g vial and mix
well
2. Add contents of vial to the 100 mL bag of 0.9% NaCl
provided
3. Infuse over one hour
Daily Maintenance
0.4 g/hour for about 24 hours in 20 mL/hour infusion
(MP or matching placebo):
1. Remove 100 mL from a 500 mL bag of 0.9% NaCl (to
make room for the steroid)
2. Add 20 mL water for injection to each of five 2 g vials
and mix well
3. Add all five (about 100 mL) to the 500 mL bag of 0.9%
NaCl
4. Infuse at 20 mL/hour for about 24 hours
5. Repeat for maintenance day 2
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N.B. As children under 16 are excluded, a simple fixed-
dose treatment can be used. The dosing regimen is that
used in the NASCIS-2 and NASCIS-3 trials of MP in
acute spinal cord injury.
Unexpected adverse events
Anaphylactic reactions to intravenous corticosteroids
are extremely rare, but should be treated in whatever
way the responsible doctor prefers (one possibility being
intra-muscular adrenaline 0.5 mg, i.e. 0.5 mL of 1 in
1,000 (1 mg/mL) solution) [14]. It would be expected
that 24-hour anaesthetic cover would be available in all
hospitals participating in CRASH. If a serious and unex-
pected adverse drug reaction occurs and is suspected to
be related to the study medicine, this should be logged by
calling the 24-hour randomisation service, who will in-
form the CRASH co-ordinating Centre in London.
In general, gastro-intestinal bleeds and infections do not
need to be reported in this way because some increase in
their incidence might be expected with steroids. Like-
wise, the various medical events that are to be expected
in head injured patients do not need to be reported by
telephone. All such events are, however, routinely moni-
tored among all patients on the outcome form.
'Unblinding' the allocated treatment in an emergency
In general there should be no need to unblind the allocat-
ed treatment. If some contra-indication to corticoster-
oids develops after randomisation (e.g. severe gastro-
intestinal bleeding), the trial treatment should simply be
stopped. Unblinding was never found to be necessary in
the NASCIS trial of MP in spinal cord injury [4], and
should be done only in those rare cases when the doctor
believes that clinical management depends importantly
upon knowledge of whether the patient received corti-
costeroid or placebo (e.g. suspected anaphylaxis). In
those few cases when urgent unblinding is considered
necessary, the randomisation service should be tele-
phoned, giving the name of the doctor authorising un-
blinding and the CRASH treatment pack number (if
available), and the caller will then be told whether the pa-
tient received corticosteroid or placebo.
Measures of outcome
The primary outcome measures are:
• Death from any cause within two weeks of injury
• Death or dependence at six months
In-hospital deaths, complications and short-term recov-
ery are to be recorded on the Early Outcome Form (Fig-
ure 3) which can be completed entirely from the hospital
notes - no extra tests are needed.
Long term recovery will be assessed at six months using
the Glasgow Outcome Scale (GOS), which assesses disa-
bility and handicap in major areas of life. The GOS will be
administered by a postal questionnaire (Figure 4), com-
pleted by a patient or carer, or by telephone interviews.
(This does not involve any additional work for collabo-
rating hospitals.)
Analysis
Comparisons will be made of the primary outcome meas-
ures, comparing all those allocated methylprednisolone
versus all those allocated placebo, on an 'intention to
treat' basis. Analyses will be stratified on time from inju-
ry to the initiation of treatment, and on severity of head
injury as assessed by the Glasgow Coma Scale. Compari-
sons will also be made of the risks of infection and gas-
trointestinal bleeding.
Organisation
The independent Data Monitoring Committee will con-
duct interim analyses of mortality and morbidity among
all trial participants. It will advise the Steering Group if
the randomised comparisons in the trial provide both (i)
proof beyond reasonable doubt of a difference in out-
come between the study and control groups, and (ii) evi-
dence that would be expected to alter substantially the
choice of treatment for patients whose doctors are, in the
light of the evidence from other randomised trials, sub-
stantially uncertain whether to give corticosteroids to
patients with head injury [15].
Collaborators' responsibilities
Co-ordination within each participating hospital will be
through a local collaborator who will:
• Discuss the trial with medical, neurosurgical and nurs-
ing staff who see trauma patients and ensure that they
remain aware of the trial and its procedures (there are
wall charts, pocket summaries and a set of slides to assist
with this)
• Ensure that adults with acute head injuries are consid-
ered promptly for the trial
Table 2: Drug or placebo treatment regimen
Treatment Vials Dose (MP or placebo)
Loading 1 2 g over 1 hour
Day 1 5 0.4 g/hour for ∼ 24 hours
Day 2 5 0.4 g/hour for ∼ 24 hours
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• Ensure that the early outcome forms are completed
Co-ordinating Centre responsibilities
• Provide study materials and a 24-hour randomisation
(and unblinding) service (Figure 5)
• Give collaborators regular information about the
progress of the study
• Help ensure complete data collection at discharge and
at six months
• Respond to any questions (e.g. from collaborators)
about the trial
Publication
The success of CRASH will be entirely dependent upon
the collaboration of nurses and doctors in the participat-
ing hospitals. Hence, the chief credit for the study will be
assigned to them in the main publications, and the col-
laborators from each participating centre will be named
personally in the main report.
Indemnity
The CRASH trial is sponsored by the Medical Research
Council (MRC) and not the manufacturers of methyl-
prednisolone. The MRC fully accepts responsibility at-
tached to its sponsorship of the trial, and as such, would
give sympathetic consideration to claims for any non-
negligent harm suffered by anyone as a result of partici-
pating in this trial.
Financial support
Medical Research Council funding covers meetings and
central organisational costs only. Pharmacia Corpora-
tion are donating drug and placebo, but the design, man-
agement and finance of the study are entirely
independent of them. Methylprednisolone is not a new
product. Really large trials of such drugs, involving many
hospitals, are important for future patients but are prac-
ticable only if those collaborating in them do so without
payment (except for recompense of any minor local costs
that may arise).
Supplement
The supplement shows the information leaflet for pa-
tients, relatives and friends, approved for use in the UK
by the multi-centre research ethics committee.
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Figure 2
 
 
   
PATIENT ENTRY 
QUESTIONS THAT WILL BE ASKED 
WHEN YOU CALL THE RANDOMISATION SERVICE 
[1] Country   
[2] Name of hospital 
where patient entered 
 
 
or
 
give your hospital code 
[3] Name of caller  
[4] Patient sex Male Female 
[5] Do you know patient’s name? Yes No  if No, go to [8] 
[6] Family name:  [7] Given name(s):  
[8] Patient Hospital Identification Number (if name unknown):  
[9] Do you know patient’s date of birth? Yes No  if No, go to [11]  
[10] Date of birth:  /     /  or, if not known: [11] Approximate age:  
[12] Estimated number of hours since injury:  
Current Glasgow Coma Scale: three questions will be asked  one or more replies must indicate an 
abnormality (if unable to assess, e.g. due to intubation, give most recent GCS) 
[13] Eye opening: 
 
[14] Motor response: 
 
[15] Verbal response: 
 
Spontaneous 
To sound 
To pain 
None 
4 
3 
2 
     1 
Obeys commands 
Localising 
Normal flexion 
Abnormal flexion 
Extending 
None 
6 
5 
4 
3 
2 
      1 
Orientated 
Confused speech 
Words 
Sounds 
None 
5 
4 
3 
2 
1 
 
[16] This GCS is: 
 1
   Current 2   Most recent 
Pupil reactiveness 
 [17] Left 
 [18] Right 
 
 1
   Yes 2   No 3   Unable to assess 
 1
   Yes 2   No 3   Unable to assess 
Now call   0800 585 323 with these answers  
and write down the treatment pack no. given at the end of the phone call 
 
Treatment Pack:  Box:  
 
Get this pack and follow the instructions on it carefully
 
This form need not be kept as source documentation 
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Figure 3
5. Management and complications
(please tick ✓ ONE box on EACH line)
Yes No
Admitted to Intensive Care Unit
If Yes, please write number of days in ICU  
Seizure
Haematemesis or melaena requiring transfusion
Wound infection with pus
Pneumonia  treated with antibiotics
Other treatment with antibiotics
Neurosurgical operation
Major extracranial injury
M
O
IS
T
E
N
 E
D
G
E
S
 A
N
D
 S
E
A
L
 T
O
G
E
T
H
E
R
M
O
IS
T
E
N
 E
D
G
E
S
 A
N
D
 S
E
A
L
 T
O
G
E
T
H
E
R
MOISTEN EDGES AND SEAL TOGETHER
EARLY OUTCOME FORM
Complete at discharge, death in hospital,
or 14 days after injury whichever occurs first
Please PRINT clearly and answer EVERY question
FOLDFOLD
6. Head CT scan   Yes    No    If No go to section 7
Date of first Time
head CT scan: / / (24 hr clock) :
Result: (please ✓ tick all that apply)
9. Family doctor
Name:
Address:
Post code:
Tel:
8. Reliable contact (Next of kin or friend)
Name:
Address:
Post code:
Tel:
7. Trial treatment          a) Loading dose:  Yes         No b) Hours of maintenance dose:  hours (1-48)
Sections 8 and 9 are only required if the patient is alive
10. Person completing form (please PRINT):
Name:   Position: Date: / /
When complete fold form as indicated, stick together and post to:
CRASH Co-ordinating Centre, FREEPOST, LON14211, London WC1N 1BR OR FAX +44 (0)20 7299 4663
CRASH/OC/3/101
1. Hospital name
2. Patient details or attach a label with these details (for 6-month follow-up)
Family name: Patient identification no. (if appropriate) 
Given name(s): NHS number (if appropriate)  
Sex:  M   F              Date of Birth: / /  (day/month/year)
Address:
Postcode: Telephone: 
3. Cause of injury:   Road traffic accident           Fall > 2 metres Other: 
 4. Outcome (please complete questions a,b,c and d)
Death Transferred to other Discharged to rehabilitation Discharged Still in this
in hospital acute care hospital centre or nursing home home hospital now
Date of death, transfer or discharge: / /
If transferred give consultant name/department, and name of hospital
Tick ✓ one box that best describes the patient’s head injury-related symptoms now (i.e. at 14 days or prior discharge):
No Minor Some restriction in Dependent, but not Fully dependent, requiring  Dead
symptoms symptoms lifestyle but independent requiring constant attention attention day and night
a.
b.
c.
d.
Attach
treatment
pack label here
Obliteration of the 3rd
ventricle or basal cisterns
Midline shift >5mm
Intracranial haematoma
– evacuated
Intracranial haematoma
– non-evacuated
One or more petechial
haemorrhages within
the brain
Cortical contusion
> 1cm in diameter
Subarachnoid bleed
Normal scan
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Figure 4
 
INTERNATIONAL STUDY OF RECOVERY AFTER HEAD INJURY 
 
These questions are about changes in your lifestyle since your injury.  They can be answered by you, a 
relative or friend, or by you both together.  If you have any questions about this form, please contact 
Senior Nurse Nin Ritchie on 020 7299 4742.  Please answer each question below by ticking one box      
which is true for you. 
Your answers will help us improve the care of people following a head injury. 
 
I need help in the home, but not 
because of the injury. 
My ability to take part is 
restricted for some other 
reason, not because of the 
injury.
There are problems for 
some other reason, not 
because of the injury. 
Thank you for your help.  Please return this form in the envelope provided to: 
Dr Ian Roberts, International Study of Recovery after Head Injury, University of London, LSHTM, 49-51 Bedford Square, London WC1B 
1. At present, where do you live most of the time? 
3. As a result of your injury, do you now need help to shop? 
No Yes.  I need some help, but can 
go to the local shops on my 
Yes.  I need help to shop 
even locally, or cannot shop 
I need help to shop, but not 
because of the injury. 
4. As a result of your injury, do you now need help to travel? 
No 
Yes.  I need some help, but can 
travel locally on my own (e.g. by 
arranging a taxi). 
Yes.  I need help to travel 
even locally, or I cannot 
travel at all. 
I need help to travel, but not 
because of the injury. 
5. As a result of your injury, has there been a change in your ability to work?  
    (or to study if you were a student; or to look after your family) 
No 
Yes.  I still work, but at a reduced 
level (e.g. a change from full-time to 
part-time, or a change in level of 
responsibility).
Yes.  I am unable to work 
at present. 
My ability to work is 
restricted , but not because 
of the injury, or I have 
6. As a result of your injury, has there been a change in your ability  
    to take part in social and leisure activities outside home? 
No Yes.  I take part a bit less, but at 
least half as often. 
Yes.  I take part much less, 
or do not take part at all.  
7. As a result of your injury, are there now problems in  
    how you get on with friends or relatives? 
No Yes.  There are occasional 
problems (less than once a 
Yes.  There are frequent 
or constant problems. 
2. As a result of your injury, do you now need help in the home? 
No 
Yes.  I need some help in the 
home, but not every day. 
Yes.  I need help in the 
home every day. 
In own home In hospital In residential care 
Please say who filled out this 
Patient Relative, friend or carer Patient and relative, friend or carer 
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Figure 5
H E A D  I N J U R Y  
w i t h  i m p a i r e d  c o n s c i o u s n e s s ?  
 
  
   
consider for the 
 
trial of steroids in head injury 
 
 
Eligibility 
 
ALL adults with head injury in past 8 hours 
and some Glasgow Coma Scale abnormality 
 
No clear indication for, or contraindication to 
steroids, in view of clinician 
 
Randomisation 
 
 
Freephone 0800 585 323 and give: 
∗ Patient name and sex 
∗ Birth date (if known) or approximate age 
∗ Hours since injury 
∗ Glasgow Coma Scale: eye opening, motor 
response, verbal response 
∗ Pupil reactiveness (Yes/No) 
 
CRASH pack number will be allocated: get 
treatment pack and follow instructions on it 
 
48-hour infusion
 
1-hour loading infusion of 100mL 
 (2g steroid or placebo in saline) 
 
48-hour infusion of 20mL/hr: (0.4g/hour 
steroid or placebo for about 48 hours) 
 
No extra tests:
 One single-sided outcome form, completed from hospital notes 
(at discharge, death in hospital, or two weeks from injury, whichever occurs first).
 
FOR 24-HOUR RANDOMISATION 
0800 585 323
 
 
